Impf_Info – Following Feed 204 Posts (gefiltert)

Reset
@NEJM 25.02 23:00
A previously healthy man presented with a 5-day history of fever, nausea, and vomiting and a 2-day history of an itchy rash. Examination showed an exanthem consisting of minute macules and subtly elevated papules. Read the full case details: https://nej.md/4tSKIiB
@NEJM 25.02 22:50
The authors of a new Perspective argue that trainees’ paths to safe, independent practice are variable. Artificial intelligence could help accelerate implementation of competency-based medical education to support individualized development. Read the Perspective by Sanjay V. Desai, MD (@sanjayvdesai), Sal Khan, MBA (@salkhanacademy), and Kimberly Lomis, MD (@KimLomisMD): https://nej.md/4cLixvZ
@NEJM 25.02 22:40
Group B streptococcal infection mostly affects newborns, infants, pregnant persons, and older adults. Perinatal prevention is successful but contributes to antibiotic exposure. Multivalent glycoconjugate vaccines are in development. Learn more in the Review Article “Group B Streptococcal Disease” by Karen M. Puopolo, MD, PhD, from @PennMedicine and @ChildrensPhila: https://nej.md/4aJJ6Pv
@NEJM 25.02 22:39
Mpox continues to spread in many communities. Tecovirimat has activity against orthopoxviruses in vitro. In a phase 3 trial involving patients with acute mpox, tecovirimat showed no evidence of clinical activity. Full STOMP/A5418 trial results: https://nej.md/4rdlMA9
@NEJM 25.02 22:20
Xin Lu, PhD, describes the scientific foundations of a study of rezatapopt, which targets a variant form of p53, to treat patients with solid tumors. Learn about the science behind the study in the editorial “Restoring Function to a Variant of p53 in Solid Tumors,” from @Ludwig_Cancer: https://nej.md/3N0pQW8
@NEJM 25.02 22:10
In a phase 1 study of the oral p53 reactivator rezatapopt in heavily pretreated patients with TP53 Y220C–mutated solid tumors, the most common adverse events were nausea and vomiting, and the overall response was 20%. Full PYNNACLE study results: https://nej.md/3OIQC5P Science behind the Study: Restoring Function to a Variant of p53 in Solid Tumors https://nej.md/3N0pQW8
@NEJM 25.02 21:00
Sounding Board: One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma https://nej.md/4tT2rqv #HealthPolicy | @US_FDA
@NEJM 25.02 19:00
In low-risk patients with severe aortic stenosis, transcatheter and surgical aortic-valve replacement led to similar 7-year survival and valve durability outcomes, with no evidence of differences in composite end points. Full PARTNER 3 trial results and Research Summary: https://nej.md/4nieHfx
@NEJM 25.02 17:01
This diagram shows the suggested diagnostic approach to disorders associated with eosinophilia. To learn more, read the latest Case Record of the Massachusetts General Hospital (@MassGeneralNews): https://nej.md/463iKqj
@NEJM @NEJMEvidence RT von @NEJM 25.02 16:20
𝐍𝐨𝐰 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐢𝐧 𝑵𝑬𝑱𝑴 𝑬𝒗𝒊𝒅𝒆𝒏𝒄𝒆! A new Public Health Alerts report, published in partnership with @CIDRAP: Multistate Infant Botulism Outbreak Associated with Powdered Infant Formula https://eviden.cc/4qXflB5 #IDTwitter #Pediatrics
@NEJM 25.02 15:00
Language discordance in surgical care is a structural driver of inequity that affects patient safety, trust, and outcomes. Emerging interpreter technologies, including #ArtificialIntelligence (AI) and remote video interpretation (RVI), are rapidly entering clinical settings. However, implementation decisions are often made without understanding how patients themselves perceive these modalities or whether they view them as replacements or complementary tools within their care. To explore Spanish-speaking surgical patients’ perceptions of AI- and RVI-based interpreter technologies, and to understand how clinical context influences modality preferences, the author team conducted a descriptive concurrent mixed-methods study within a U.S. academic health system, enrolling 23 adult patients with Spanish language preference across the surgical continuum. The patients did not choose a single preferred modality; instead, they expressed context-dependent needs. AI was viewed as advantageous for its speed, privacy, and literal translation in straightforward or time-sensitive scenarios. RVI was favored for emotionally complex conversations and cultural nuance. Across narratives, patient agency emerged as a dominant theme. These findings support the development of a multifaceted language access infrastructure in which AI and remote human interpreters are deployed synergistically based on clinical sensitivity, urgency, and patient preference. Read the In Depth article “Artificial Intelligence for Language Access in Surgical Care: Patient Preferences and an Implementation Framework” by M.A. Montoya Rubiano et al. in the March 2026 issue of @nejmcatalyst Innovations in Care Delivery: https://nej.md/46XDy2K Explore the full issue: https://nej.md/40e5VG6
@NEJM 25.02 14:00
The risk of recurrent ischemic stroke can be reduced by managing modifiable risk factors and instituting a regimen of mechanism-specific secondary stroke prevention. Strategies for secondary prevention should be instituted as early as possible. Learn more: https://nej.md/3OFpJ2C
@NEJM 24.02 22:00
Perspective by Jessica S. Ross, MD: Heads or the Tail? https://nej.md/3MJWJ9r #MedicalEthics #MedicalPractice
@NEJM 24.02 20:00
𝐁𝐢𝐝𝐢𝐫𝐞𝐜𝐭𝐢𝐨𝐧𝐚𝐥 𝐭𝐫𝐚𝐧𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 is a process in which both strands of DNA at a given locus are transcribed, producing RNA in opposite directions from the same region. Sense and antisense transcripts are thereby generated. Bidirectional transcription is a common feature of genomic regions with repeat expansions and can contribute to disease by generating toxic RNAs or proteins from both strands. To learn more about this NEJM Illustrated Glossary term, read the editorial “A Trial of an Antibody–Oligonucleotide Conjugate” by Laura P.W. Ranum, PhD, from @UFMedicine, @UFMBI, @FixelInstitute, and @UFGenetics: https://nej.md/4aic8XJ Explore more terms: https://nej.md/glossary
@NEJM 24.02 17:01
Johnson and colleagues report a phase 1–2 trial of del-desiran, an antibody–oligonucleotide conjugate designed to reduce DMPK mRNA, to treat myotonic dystrophy type 1. Full MARINA trial results and Research Summary: https://nej.md/4tBOFbu
@NEJM @NEJMEvidence RT von @NEJM 24.02 15:14
Volume 5 Issue 3 of 𝘕𝘌𝘑𝘔 𝘌𝘷𝘪𝘥𝘦𝘯𝘤𝘦 is now available! Here is a preview of the latest content: 𝗣𝘂𝗯𝗹𝗶𝗰 𝗛𝗲𝗮𝗹𝘁𝗵 𝗔𝗹𝗲𝗿𝘁𝘀 Seasonal Influenza Activity, Vaccination Rates, and Pediatric Influenza Mortality, Massachusetts 2024–2025 https://eviden.cc/3Ng77px
@NEJM 24.02 15:00
Images in Clinical Medicine: Majocchi’s Granuloma https://nej.md/4qCbUiO #DermTwitter #IDTwitter
@NEJM 24.02 14:00
Correspondence: Revival of Ethionamide by Alpibectir https://nej.md/46PP9Rn #IDTwitter #GlobalHealth
@NEJM 23.02 22:00
After ischemic stroke, recurrence risk is reduced by identifying the stroke mechanism and targeting modifiable risk factors. Early diagnostic evaluation, prompt preventive therapy, and ongoing monitoring are central to care. Learn more: https://nej.md/3OFpJ2C
@NEJM 23.02 21:00
In a Perspective, Sonja A. Rasmussen, MD, and Daniel B. Jernigan, MD, MPH, write that both viral and host factors have contributed to the intensity of influenza activity during the 2025–2026 season. Some of these factors can be managed, whereas others are largely beyond human control. Learn more: https://nej.md/49VN4pc
@NEJM 23.02 20:00
The PARTNER 3 trial showed similar outcomes of transcatheter aortic-valve replacement and surgical aortic-valve replacement for severe, symptomatic aortic stenosis in low-risk patients at 5 years. Now, 7-year findings are summarized in a new Quick Take video. https://nej.md/4twDktn
@NEJM 23.02 17:00
In relapsed or refractory multiple myeloma, teclistamab plus daratumumab significantly prolonged progression-free survival as compared with DPd or DVd (83.4% vs. 29.7%) and led to higher response rates. Full phase 3 MajesTEC-3 trial results and Research Summary: https://nej.md/4431DUD
@NEJM 23.02 15:00
From an Original Article published March 1, 1956: Early in the present century lesions of the peripheral nerves caused by arsenical intoxication were a frequent occurrence. In most cases the neuropathy could be attributed to contact with the many household articles such as dyes, wallpaper and insecticides that contained large quantities of arsenic. In recent years, exposure to arsenic has been greatly reduced, and arsenical intoxication is no longer considered a common cause of peripheral neuropathy. Dusts and sprays containing arsenic, however, continue to be extensively employed as pesticides on farms in North Carolina, and their accidental ingestion or inhalation has produced numerous cases of poisoning. Our experience with this condition suggests that arsenical intoxication may be a more frequent cause of neuropathy, particularly in rural areas, than is generally realized. The present paper analyzes 41 cases of acute and chronic arsenical poisoning with peripheral neuropathy seen in Duke University Hospital and Durham Veterans Administration Hospital during the past fifteen years. The clinical and laboratory diagnosis of this condition is emphasized. Special attention is also given to the effects of BAL therapy of the neuropathy since there is little information on the value of this commonly recommended agent. Continue reading “Peripheral Neuropathy Caused by Arsenical Intoxication — A Study of 41 Cases with Observations on the Effects of Bal (2,3, Dimercapto-Propanol),” an article from 1956, in the NEJM Archive: https://nej.md/4rhDfIn
@NEJM 23.02 14:00
Images in Clinical Medicine: Peritoneal Coccidioidomycosis https://nej.md/4aykJ7y #IDTwitter
@NEJM 22.02 22:00
A new Video in Clinical Medicine reviews the key aspects of patient-controlled analgesia device usage, including the indications and contraindications, routes of administration, and essential equipment required. Watch the full video and read the accompanying article: https://nej.md/46POEXv
@NEJM 22.02 21:00
MARINA trial: Myotonic dystrophy type 1 currently has no approved therapies. Research on the safety of delpacibart etedesiran ― an antibody–oligonucleotide conjugate developed to treat the underlying cause of the disorder ― is summarized in a new Quick Take video. https://nej.md/4aLHnuh
@NEJM 22.02 20:00
Science behind the Study: A Trial of an Antibody–Oligonucleotide Conjugate https://nej.md/4aic8XJ #Neurology #Genetics
@NEJM 22.02 17:00
A previously healthy 26-year-old man presented with a 5-day history of fever, nausea, and vomiting and a 2-day history of an itchy rash. The rash had started behind his ears and then spread to his face and entire body. The patient was a refugee from a Middle Eastern country and had had limited vaccinations. Well-demarcated erosions were also present on the buccal mucosa on both sides of the mouth. Submit your answer or see how others responded: https://nej.md/IC02192026
@NEJM @NEJMEvidence RT von @NEJM 22.02 15:05
“... treatment with solriamfetol had a significant impact on sleep latency; while there was an increase in sleep latency in both groups, the solriamfetol group had an additional 9.4 minutes of sleep latency [vs. placebo], which was sustained.” https://eviden.cc/4ruRPft
@NEJM 22.02 14:00
Case Record of the Massachusetts General Hospital (@MassGeneralNews): A 91-year-old man was admitted to the hospital with weight loss, dyspnea, and eosinophilia. An anteroposterior chest radiograph obtained 2 months earlier showed bibasilar patchy opacities. A diagnosis was made. 👉 https://nej.md/463iKqj An anteroposterior image obtained on portable chest radiography 2 months before the current admission (Panel A) shows new bibasilar patchy opacities (arrows), which are more prominent in the right lung than in the left lung, a finding that suggests pneumonia or aspiration (or both) in both lungs. A posteroanterior chest radiograph obtained on the day of admission (Panel B) shows a decrease in the size of the opacities in the right lower lobe and no change in the size of the opacities in the left lower lobe (white arrows), along with new small bilateral pleural effusions (black arrows). Read the full case details in “A 91-Year-Old Man with Shortness of Breath, Weight Loss, and Eosinophilia,” a Case Record of the Massachusetts General Hospital, by P.K. Bendapudi et al., from Massachusetts General Hospital (@MassGeneralNews) and @harvardmed: https://nej.md/463iKqj
@NEJM 21.02 22:00
Reducing Tobacco Use Worldwide by Laura Llambi, MD, PhD (@laura_llambi), and Paola Morello, MD, MPH: Tobacco Cessation among Nondaily and Low-Intensity Smokers — Challenges and Opportunities in Latin America https://nej.md/4qMcevK #GlobalHealth #HealthPolicy
@NEJM 21.02 21:00
Original Article: Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years (PARTNER 3 trial) https://nej.md/4nieHfx #Surgery #Cardiology
@NEJM 21.02 20:00
Original Article: An Antibody–Oligonucleotide Conjugate for Myotonic Dystrophy Type 1 (MARINA trial) https://nej.md/4tBOFbu Science behind the Study: A Trial of an Antibody–Oligonucleotide Conjugate https://nej.md/4aic8XJ #Neurology #Genetics
@NEJM @NEJMEvidence RT von @NEJM 21.02 18:07
In a follow-up to a study of pregnant individuals at high risk of hemolytic disease of the fetus & newborn, antenatal nipocalimab treatment resulted in low levels of detectable drug in fetal, neonatal & infant samples, w/ no unusual childhood illnesses. https://eviden.cc/46bss9Y
@NEJM 21.02 17:00
This Sounding Board announces a new @US_FDA policy that the default requirement for FDA approvals will be one robust pivotal trial plus confirmatory evidence, rather than two trials. Learn more: https://nej.md/4tT2rqv
@NEJM 21.02 16:00
Ischemic stroke, defined as a central nervous system injury caused by loss of blood flow, is most often due to arterial thromboembolism. Evaluation should include relevant blood tests and cardiovascular and cardiac investigations (seen in table). Learn more: https://nej.md/3OFpJ2C
@NEJM 21.02 15:00
A high-school wrestler presented with an itchy rash that had worsened despite topical antifungal and glucocorticoid treatment. A circular, scaly plaque with papules, nodules, and pustules was seen on his calf. Read the full case details in the Images in Clinical Medicine article “Majocchi’s Granuloma,” from @nyulangone and @nyugrossman: https://nej.md/4qCbUiO
@NEJM 21.02 14:00
Sonja A. Rasmussen, MD, discusses the 2025–2026 influenza season, including factors contributing to the intensity of influenza activity. Listen to the full interview with NEJM Executive Managing Editor Stephen Morrissey (@srm128): https://nej.md/4rhH400
@NEJM 20.02 22:00
Original Article: Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges (phase 3 LATITUDE trial) https://nej.md/4qFyjMm Editorial: From Efficacy to Access in Long-Acting HIV Therapy https://nej.md/4rRRyTT #IDTwitter
@NEJM 20.02 21:00
Patients with relapsed or refractory multiple myeloma often face limited durable treatment options. Phase 3 MajesTEC-3 trial results are summarized in a new Quick Take video. https://nej.md/409MNsU
← zurück Seite 5 / 6 2 3 4 5 6 weiter →